Galmed Pharmaceuticals Ltd.
Close on Oct 19, 2026
- Market cap
- $2.71M
- P/E (TTM)
- 0.1
- Dividend yield
- –
About Galmed Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics. Its lead investigational candidate is Aramchol, a compound historically evaluated for the treatment of non-alcoholic steatohepatitis and liver fibrosis. The company is actively working to advance Aramchol into oncological indications outside of liver disorders. In addition, it seeks to broaden and diversify its product development pipeline by targeting innovative candidates for cardiometabolic diseases. Because Galmed remains in the clinical development stage without approved commercial therapies, it operates without conventional commercial end-customer sales and relies primarily on licensing agreements and research collaborations.
The company conducts its operations from the State of Israel, maintaining its principal executive offices and headquarters in Ramat Gan. Galmed operates as a development-stage biopharmaceutical enterprise with a small core team of executive management, carrying out research, preclinical, and clinical trial activities through relationships with specialized third-party service providers.
Summary of the business section of Galmed Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Galmed Pharmaceuticals Ltd.
- Founded
- 2000
- Headquarters
- Ramat Gan, L3
- Address
- C/O Meitar Law Offices, 16 Abba Hillel Silver Rd. 5250608
- Phone
- 97236938448
- Website
- galmedpharma.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- EOCN
- Exchange
- Nasdaq
- IPO date
- Mar 13, 2014
- Shares outstanding
- 7M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-8 reverse, Sep 2, 2026; 1-for-8 reverse, Aug 19, 2026; 1-for-12 reverse, Apr 2, 2025; 1-for-12 reverse, Aug 30, 2024; 1-for-15 reverse, Aug 9, 2023; 1-for-15 reverse, May 15, 2023
- SEC CIK
- 1595353
- EIN
- 98-1147233
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Allen Baharaff | Chief Executive Officer, Director | 100,018 |
| Guy Nehemya | Chief Operating Officer | 25,000 |
| Yohai Stenzler | Chief Accounting Officer | 25,000 |
| Doron Leib Cohen | Chief Financial Officer | 2,083 |
| Brueck Liat Nissimov | Chief Scientific Officer | – |
| Amir Poshinski | Director | 12,500 |
| Carol L. Brosgart | Director | – |
| Shmuel Nir | Director | 12,500 |
| David Sidransky | Director | 1,042 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had six employees, of which three were full-time employees and three were part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 13, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 11, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |